Abstract | AIMS: METHODS: Pharmacokinetic parameters were assessed for flutamide and hydroxyflutamide in 26 male subjects with normal renal function ( creatinine clearance by 24 h urine collection, CLcr, greater than 80 ml min(-1) 1.73 m(-2); n=6) or reduced renal function; CLcr=50-80 (n=7), 30-49 (n=3), 5-29 (n=4), and <5 ml min(-1) 1.73 m(-2)-HD (n=6), following a single, oral 250 mg flutamide dose. Subjects undergoing HD received a second 250 mg dose of flutamide 4 h prior to HD; blood and dialysate were collected during HD to determine dialysability of flutamide and hydroxyflutamide. RESULTS: CONCLUSIONS:
|
Authors | S Anjum, S K Swan, L J Lambrecht, E Radwanski, D L Cutler, M B Affrime, C E Halstenson |
Journal | British journal of clinical pharmacology
(Br J Clin Pharmacol)
Vol. 47
Issue 1
Pg. 43-7
(Jan 1999)
ISSN: 0306-5251 [Print] England |
PMID | 10073738
(Publication Type: Journal Article)
|
Chemical References |
- Androgen Antagonists
- hydroxyflutamide
- Flutamide
|
Topics |
- Androgen Antagonists
(adverse effects, pharmacokinetics)
- Area Under Curve
- Flutamide
(adverse effects, analogs & derivatives, pharmacokinetics)
- Half-Life
- Humans
- Male
- Middle Aged
- Renal Dialysis
- Renal Insufficiency
(metabolism)
|